Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Enochian BioSciences Inc. (ENOB : NSDQ)
 
 • Company Description   
Enochian BioSciences Inc. engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of HIV and cancer. The company's product pipeline consists of ENO-1001, ENO-2001, ENO-3001, ENO-1002, ENO-5001 and ENO-4001. Enochian BioSciences Inc. is based in Los Angeles, United States.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.26 Daily Weekly Monthly
20 Day Moving Average: 262,063 shares
Shares Outstanding: 52.95 (millions)
Market Capitalization: $331.47 (millions)
Beta: 0.43
52 Week High: $13.78
52 Week Low: $3.70
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.70% -8.44%
12 Week -6.29% 3.02%
Year To Date -14.13% 1.07%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2080 Century Park East Suite 906
-
Los Angeles,CA 90067
USA
ph: 305-918-1980
fax: -
ir@enochianbio.com http://www.enochianbio.com
 
 • General Corporate Information   
Officers
Mark Dybul - Chief Executive Officer
Rene Sindlev - Director and Chairman
Luisa Puche - Chief Financial Officer
Carl Sandler - Director
James Sapirstein - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29350E104
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/23/22
Share - Related Items
Shares Outstanding: 52.95
Most Recent Split Date: (:1)
Beta: 0.43
Market Capitalization: $331.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.06
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -116.67%
vs. Previous Quarter: 35.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -24.27
12/31/21 - -22.93
09/30/21 - -20.87
ROA
03/31/22 - -22.02
12/31/21 - -21.02
09/30/21 - -19.29
Current Ratio
03/31/22 - 1.56
12/31/21 - 2.36
09/30/21 - 12.76
Quick Ratio
03/31/22 - -
12/31/21 - 2.36
09/30/21 - 12.76
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.05
12/31/21 - 3.17
09/30/21 - 3.20
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.01
09/30/21 - 0.04
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.72
09/30/21 - 3.39
 

Powered by Zacks Investment Research ©